Practice Patterns of Usage of Glimepiride and Metformin FDC Along with Other OADs: A New Age Approach to Diabetes Management in Indians

Main Article Content

Dr J George
Dr Ganesh HK
Dr V Ghatnatti
Dr C Sujit
Dr Vimal MV
Dr Manohar KN
Dr M Anakal
Dr A Mahule
Dr A Prasad
Dr A Pednekar
Dr Aushili M

Abstract

Diabetes is a progressive disease managed by different oral antidiabetic drugs
(OADs) with or without glimepiride/metformin. As diabetes continues to be a significant health
concern in India, novel therapeutic strategies are essential to effectively control the disease and
improve patient outcomes. New drugs like sodium-glucose cotransporter-2 inhibitors (SGLT2i)
and dipeptidyl peptidase-4 inhibitors (DPP-4i) have intermediate efficacy. Understanding


clinicians’ prescription patterns is crucial for optimizing treatment strategies for better long-
term type 2 diabetes mellitus (T2DM) control. Methods: This was a retrospective, multicenter,


observational case-based questionnaire study on T2DM patients undergoing pharmacotherapy. It
aimed to collect data on clinical utilization patterns of glimepiride and metformin FDC (fixed-dose
combination) with other OADs and comorbidities. The study included responses from 500 health
care professionals (HCPs) across India. Statistical analysis was performed using SPSS® Version 23.0
software. Independent t-test was used to compare the change in fasting plasma glucose (FPG),
postprandial plasma glucose (PPG), and glycated hemoglobin (HbA1c) between two groups and
Fisher’s exact and Chi-square tests were used to compare categorical variables. P-value <0.05 was
considered statistically significant. Results: The study analysis included responses from 500 HCPs.
It showed that 6,250 patients received glimepiride/metformin FDC. The HbA1c was found to be
8.81% before treatment, which decreased to 7.75% after treatment. Among the 6,250 patients, 1,704
patients also recieved other OADs, where some patients recieved more thn one OADs. DPP4i was
prescribed the most (1,064 patients followed by sodium-glucose cotransporter 2 inhibitors (SGLT2i)
(573 patients), pioglitazone (229 patients), alpha-glucosidase inhibitor (AGI) (207 patients), insulin
(178 patients), and lastly glucagon-like peptide 1 receptor agonist (GLP1RA) being prescribed in
35 patients along with the combination. Hypoglycemia was observed in very few patients (4.49%).
Hypertension was the most prevalent (60.5%) comorbidity in the studied patient population.
Conclusion: Use of glimepiride and metformin FDC along with other OADs offer optimized
glycemic control, promote weight loss, and help to reduce complications in patients with T2DM.

Article Details

Section

Clinical Study

Similar Articles

You may also start an advanced similarity search for this article.

Most read articles by the same author(s)